Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Summary

This phase II MATCH treatment trial identifies the effects of dasatinib in patients whose cancer has a genetic change called DDR2 mutation. Dasatinib may block proteins called tyrosine kinases, which may be needed for cancer cell growth. Researchers hope to learn if dasatinib will shrink this type of cancer or stop its growth.

Timeline

Start

2016-02-25

Primary completion

2018-06-07

Completion

—

Outcome

Outcome not reported

Stopped (Enrollment): “zero accrual”

Drugs

Indications